CommBio Therapeutics is dedicated to developing a new class of medicine – bacterial vector gene therapy, for a spectrum of complex diseases that currently lack solution
Find out MoreCommBio has established multiple proprietary technology platforms to support bacterial vector gene therapy drug development
Find out MoreOur product portfolio includes two pipelines: Drug (6 Candidates) and Consumer Product (3 Candidates)
Find out More
First global technological standard for engineered bacteria being released in Zhangjiang
CommBio's CSO Dr. Peter Atadja presents at the 25th Shanghai International Forum on Biotechnology & Pharmaceutical Industry
CommBio named “top 10 biotech with most growth potential”
CommBio CEO Dr. Bin Xiang interviewed by Shanghai Techology
15
2023-0615
2023-0613
2023-0611
2023-05
To pioneer and become the leading company in the application of bacterial vector gene therapy to meet the medical needs of patients in the Chinese and global markets.
To bring high quality, first-in-class and best-in-class therapeutics to patients in China and worldwide that are safe, effective and affordable by a restless and relentless dedication to innovation.
CommBio Therapeutics Co., Ltd 沪ICP备2021004953号-1
